Nurix Therapeutics, Inc.
1700 Owens Street
Suite 205
San Francisco, CA 94158
United States
415 660 5320
https://www.nurixtx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 284
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | CEO, President & Director | 986.32k | 無 | 1962 |
| Mr. Johannes Van Houte | Chief Financial Officer | 681.98k | 無 | 1966 |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer | 702.75k | 無 | 1971 |
| Dr. John Kuriyan Ph.D. | Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Mr. Michael Rapé Ph.D. | Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Dr. Arthur Weiss M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Rita Kwong | Senior Accounting Manager | 無 | 無 | 無 |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary & Chief Compliance Officer | 595.83k | 599.89k | 1965 |
| Mr. Eric C. Schlezinger J.D. | Chief People Officer | 無 | 無 | 1967 |
| Dr. Jason Kantor Ph.D. | Chief Business Officer | 無 | 無 | 無 |
描述
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
公司管治
截至 2024年4月1日 止，Nurix Therapeutics, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：8；董事會：5；股東權利：8；現金賠償：10。
